# US 2026/0015671 A1 · Method for detecting lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0015671 A1
- Document ID: US20260015671A1
- Status: Published application
- Kind: A1
- Application number: 18/870,266
- Filed: 2023-05-25
- Published: 2026-01-15
- Earliest claimed: 2022-05-27
- Applicants: Genomictree, Inc.
- Inventors: Sunghwan AN; TaeJeong OH
- Web page: https://patentgrep.com/patent/US20260015671A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for providing information for lung cancer diagnosis, a composition for diagnosing lung cancer, and a kit comprising same and, more specifically, to a method for providing information for lung cancer diagnosis by using a primer for specifically amplifying a plurality of methylated lung cancer marker 5 genes, a composition for diagnosing lung cancer, and a kit comprising same.

## Claims

### Claim 1

A method for lung cancer diagnosis, comprising the following steps:
(a) treating a sample with one or more reagents that differentially modify the methylated PCDHGA12 (Protocadherin Gamma Subfamily A, 12) gene and the CDO1 (Cysteine Dioxygenase Type 1) gene, the unmethylated PCDHGA12 gene and the CDO1 gene; and (b) treating a primer that specifically amplifies the methylated PCDHGA12 gene and the CDO1 gene.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the reagent is bisulfite, hydrogensulfite, disulfite, or a combination thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the reagent treatment converts at least one cytosine base to a base different from uracil or cytosine.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the primer that specifically amplifies the methylated CDO1 gene comprises the primer pair of SEQ ID Nos: 4 and 5.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the primer that specifically amplifies the methylated CDO1 gene comprises the primer pair of SEQ ID Nos: 1 and 2.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method comprises the step (c) of processing a probe capable of complementarily hybridizing to the methylated PCDHGA12 gene and the methylated CDO1 gene, respectively, specifically amplified by the primer in step (b) above.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the probe capable of hybridizing complementarily to the amplified methylated CDO1 gene may comprise, for example, a sequence of SEQ ID NO: 6.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the probe capable of hybridizing complementarily to the amplified methylated PCDHGA12 gene comprises the sequence of SEQ ID NO: 3.

### Claim 9 (depends on 1)

The method according to claim 1, wherein methylation detection is performed by a method selected from the group consisting of PCR, methylation specific PCR, real time methylation specific PCR, PCR using a methylation DNA specific binding protein, PCR using a methylation DNA specific binding antibody, quantitative PCR, gene chip, sequencing, sequencing by synthase, and sequencing by ligation.

### Claim 10 (depends on 6)

The method according to claim 6, wherein methylation is detected by detecting a substance that binds to the probe and exhibits fluorescence.

### Claim 11

A composition for diagnosing lung cancer, comprising one or more reagents that differentially modify the methylated PCDHGA12 (Protocadherin Gamma Subfamily A, 12) gene and the CDO1 (Cysteine Dioxygenase Type 1) gene, the unmethylated PCDHGA12 gene and the CDO1 gene; and a primer that specifically amplifies the methylated PCDHGA12 gene and the CDO1 gene.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the reagent is bisulfite, hydrogensulfite, disulfite, or a combination thereof.

### Claim 13 (depends on 11)

The composition according to claim 11, wherein the reagent converts at least one cytosine base to a base different from uracil or cytosine.

### Claim 14 (depends on 11)

The composition according to claim 11, wherein the primer that specifically amplifies the methylated CDO1 gene comprises the primer pair of SEQ ID Nos: 4 and 5.

### Claim 15 (depends on 11)

The composition according to claim 11, wherein the primer that specifically amplifies the methylated CDO1 gene comprises the primer pair of SEQ ID Nos: 1 and 2.

### Claim 16 (depends on 11)

The composition according to claim 11, which further comprises a probe capable of complementarily hybridizing to the methylated PCDHGA12 gene and the methylated CDO1 gene, respectively, specifically amplified by the primer.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein the probe capable of hybridizing complementarily to the amplified methylated CDO1 gene comprises the sequence of SEQ ID NO: 6.

### Claim 18 (depends on 16)

The composition according to claim 16, wherein the probe capable of hybridizing complementarily to the amplified methylated PCDHGA12 gene comprises the sequence of SEQ ID NO: 3.

### Claim 19 (depends on 11)

A kit for diagnosing lung cancer comprising the composition according to claim 11.
